Gyre Therapeutics (GYRE) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Helus Pharma (HELP) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 71.2% versus a loss of 7.4%. Over five years, HELP leads with a -85.7% price change compared with -88.7% for GYRE. Helus Pharma is the larger company by market cap ($783.2 million vs $716.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | HELP |
|---|---|---|
| Share price | $6.76 | $10.72 |
| Market cap | $716.79M | $783.21M |
| 1-day change | -3.98% | +2.00% |
| YTD return | -4.25% | +31.05% |
| 1-year return | -7.40% | +71.25% |
| 5-year return | -88.73% | -85.68% |
| Forward P/E | 112.67 | — |
| EPS (TTM) | $-0.25 | $-4.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $15.15 |
| 52-week low | $5.44 | $3.76 |
| Distance from 52-week high | -28.24% | -29.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.18% | +271.55% |
| Average volume | 105.93K | 1.77M |
| Shares outstanding | 106.03M | 73.06M |
| Employees | 625 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed GYRE by 78.6 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
GYRE vs HELP FAQ
Which is bigger, Gyre Therapeutics or Helus Pharma?
Helus Pharma (HELP) is larger, with a market capitalization of $783.21M compared with $716.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or HELP?
HELP returned +71.25% over the past 12 months, compared with -7.40% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Helus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.